title: Acyclic retinoid synergises with valproic acid to inhibit growth in human hepatocellular carcinoma cells.
abstract: A malfunction of retinoid X receptor-alpha (RXRalpha) due to phosphorylation is associated with the development of hepatocellular carcinoma (HCC) and acyclic retinoid (ACR), which targets RXRalpha, can prevent the development of second primary HCC. Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, induces apoptosis and cell cycle arrest in cancer cells. VPA can also enhance the sensitivity of cancer cells to retinoids. The present study examined the possible combined effects of ACR plus VPA in HepG2 human HCC cell line. The combination of 5muM ACR and 1mM VPA, about the IC(25) value for both compounds, synergistically inhibited the growth of HepG2 cells without affecting the growth of Hc normal human hepatocytes. The combined treatment with ACR plus VPA also acted synergistically to induce apoptosis and G(0)-G(1) cell cycle arrest in HepG2 cells. This combination further exerted a synergistic inhibition of the phosphorylation of RXRalpha, ERK, Akt and GSK-3beta proteins and caused an accumulation of acetylated histones H3 and H4 proteins. VPA enhanced the ability of ACR to raise the cellular levels of RARbeta and p21(CIP1). The combination of these agents markedly increased both the RARE and RXRE promoter activities in HepG2 cells. These results suggest that ACR and VPA cooperatively increase the expression of RARbeta and p21(CIP1), while inhibiting the phosphorylation of RXRalpha, and these effects were associated with induction of apoptosis and the inhibition of cell growth in HepG2 cells. This combination might therefore be an effective regimen for the chemoprevention and chemotherapy of HCC.
authors.affiliation: Department of Medicine, Gifu University Graduate School of Medicine, Gifu 501-1194, Japan.
authors.forename: Hideharu
authors.initials: H
authors.lastname: Tatebe
authors.forename: Masahito
authors.initials: M
authors.lastname: Shimizu
authors.forename: Yohei
authors.initials: Y
authors.lastname: Shirakami
authors.forename: Hiroyasu
authors.initials: H
authors.lastname: Sakai
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Yasuda
authors.forename: Hisashi
authors.initials: H
authors.lastname: Tsurumi
authors.forename: Hisataka
authors.initials: H
authors.lastname: Moriwaki
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D015153:Blotting, Western; D006528:Carcinoma, Hepatocellular / Q000378:metabolism*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004357:Drug Synergism; D006801:Humans; D020287:In Situ Nick-End Labeling; D008113:Liver Neoplasms / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014212:Tretinoin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D014635:Valproic Acid / Q000008:administration & dosage*
chemical_list: D014212:Tretinoin; D014635:Valproic Acid; C034534:3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid